IP Library › Granted Patent US 9,902,945
Granted Patent B2
US 9,902,945 · App. 14/429,637 · Granted Feb 27, 2018

Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GEMVAX & KAEL CO., LTD.
C12N9/1276A23L33/18A61K8/66A61K47/48246A61K49/0002A61K49/0043A61K49/0056A61Q19/00C07K7/08C07K14/00G01N33/582A23V2002/00A61K38/00A61K2800/57C07K2319/10G01N2458/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,945
App. No.
14/429,637
Granted
Feb 27, 2018
Kind
B2
Abstract

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Claims (7)

1. A conjugate consisting of a mitochondrial targeting peptide and ferrocene carboxylate, wherein said mitochondrial targeting peptide consists of 30 amino acids or less.

2. The conjugate of claim 1 , wherein the mitochondrial targeting peptide is derived from human telomerase reverse transcriptase (hTERT) enzyme.

3. The conjugate of claim 2 , wherein the mitochondrial targeting peptide comprises SEQ ID NO: 48.

4. The conjugate of claim 1 , wherein the mitochondrial targeting peptide and ferrocene carboxylate are combined via a covalent bond.

5. The conjugate of claim 1 , wherein the mitochondrial targeting peptide and ferrocene carboxylate are combined via a non-covalent bond.

6. A contrasting agent comprising the conjugate of claim 1 .

7. A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036070/0325 →
Priority Claims (5)
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104173 · Sep 19, 2012 · national
KR 10-2012-0109207 · Sep 28, 2012 · national
KR 10-2012-0109216 · Sep 28, 2012 · national
KR 10-2013-0017169 · Feb 18, 2013 · national
Continuity (1)
Related Publication 20150307859A1 · Oct 29, 2015